Siga Technologies Inc.

SIGA Healthcare Drug Manufacturers Specialty & Generic

Siga Technologies Inc.’s revenue for fiscal 2025 (year ended December 2025) was $94.6 million, down 31.8% from fiscal 2024. In the quarter to June 2026, revenue fell 49.5%, EPS fell 66.0% and free cash flow fell 76.0%, each against the same quarter a year earlier. Dividend growth for five consecutive years.

3.17 0.02 −0.63%
Market cap
$229.2M
P/E
0.0×
Fwd P/E
28.7×
Dividend yield
0.00%
F-score
5/9
Altman Z
14.28
Beneish M
−4.02
Dividend safety
36/100

An Income Statement, also known as a Profit and Loss Statement, summarizes a company's revenues, expenses, and profits over a specific period. It highlights how revenue is transformed into net income, showcasing operational efficiency. Key components include total revenue, cost of goods sold (COGS), gross profit, operating expenses, and net profit. Businesses use the Income Statement to assess financial performance, make strategic decisions, and ensure profitability. Investors and stakeholders analyze it to gauge the company’s financial health and future growth potential.

Jun '26 Mar '26 Dec '25 Sep '25 Older periods
Revenue
41.00 6.24 3.79 2.62

+8 more quarters

Revenue Growth
(49.45%) (11.34%) (95.34%) (73.83%)
Gross Profit
23.44 3.30 0.80 1.62
Operating Income
13.91 (5.32) (9.50) (10.22)
EBT
14.85 (4.04) (7.96) (8.36)
Income after Tax
12.46 (3.45) (5.43) (6.37)
Net Income Common
12.46 (3.45) (5.43) (6.37)
EPS (Diluted)
0.17 (0.05) (0.08) (0.09)
Shares (Diluted, Weighted)
71.88 71.65 71.87 71.61
Gross Margin
57.17% 52.89% 21.20% 61.75%
EBIT Margin
33.91% (85.24%) (250.38%) (390.18%)
Net Profit Margin
30.40% (55.33%) (143.11%) (242.97%)
EBITDA
14.06 (5.17) (9.35) (10.08)
EBIT
13.91 (5.32) (9.50) (10.22)

Show all line items

In millions of $ except per-share values · columns are period end dates